The UK has a long history of vaccine research, but has not always had a clear pathway for new vaccines to move from discovery to licensed product. Under one roof this unique facility, operated by our experts, will promote, develop and accelerate the growth of the vaccine industry.
The idea of VMIC is born.
University of Oxford, Imperial College, and London School of Hygiene and Tropical Medicine, with support from vaccine industry experts MSD, Johnson and Johnson, and Cytiva establish VMIC.
UK Government provides funding for the capital project and temporary offices are set up at Oxford Science Park.
The Jenner Institute called on VMIC experts to set up the first UK consortium for the Oxford COVID-19 vaccine. This consortium drove the process and manufacturing scale up of the Oxford vaccine. This work continued through to 2021 with VMIC experts supporting the technology transfer at which point the work was handed over to AstraZeneca.
Construction of the 74,000 square metre footprint VMIC facility begins on the Harwell Science and Innovation Campus, Oxfordshire.
The UK Government directs VMIC to expand the facility’s vaccines production capabilities by nearly 20-fold, to fast-track the development schedule, and to create ‘Virtual VMIC’ while the main facility is being built.
VMIC signs first industry partnership with Oxford Biomedica under the ‘Virtual VMIC’ Programme to establish a manufacturing site for the Oxford/ AZ vaccine to support the government’s national vaccination programme. VMIC provides expertise and equipment to set up the site in Oxford.
UK Prime Minister Boris Johnson visits the VMIC facility at Harwell Campus to tour the site and thank the VMIC team for their ground-breaking work on the Oxford/AZ vaccine during the COVID-19 pandemic.
Virtual VMIC suites awarded GMP status and begin production at a 1000L scale of the Oxford/AstraZeneca vaccine that is used to vaccinate the UK population.
VMIC’s facility reaches base build completion.
VMIC, as part of the Bio-Industry Association COVID-19 Vaccine Manufacturing Taskforce receives the Richard Wilson Impact Award at the 17th Annual BioProcess UK Conference 2020 for their work during the COVID-19 pandemic.
The VMIC team grows to 60 people and establishes a temporary laboratory to begin preparation of Quality Control work that includes installation and qualification of analytical equipment required to support the facility/utility qualification.
Equipment is purchased, validated and tested from around the world, and within the UK, to begin fitting out the VMIC facility and advancing it towards operational readiness.
Looking ahead to 2022
VMIC will become operational – ready to work with vaccine discoverers and developers through to commercial partners, in the UK and around world.